Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crown

Showing results (151-160 of 188) with videos related to

Pageof 19
Sort By:
Oncotarget|October 25, 2016
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancerSinead Toomey, Stephen F Madden, Simon J Furney, et al.
Journal of the National Cancer Institute|January 10, 2008
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trialPrudence Francis, John Crown, Angelo Di Leo, et al.
Clinical Lung Cancer|January 19, 2025
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket TrialJonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, et al.
Acta Oncologica (Stockholm, Sweden)|April 22, 2024
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter studyRosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, et al.
Breast Cancer Research : BCR|May 4, 2012
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialLynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerAmir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
International Journal of Cancer|April 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studiesJosé A García-Saenz, Gonzalo Spera, Marina Pollán, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2018
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 TrialYoussef H Zeidan, Joyce G Habib, Lieveke Ameye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.
Pageof 19

Showing results (151-160 of 188) with videos related to

Sort By:
Pageof 19
Oncotarget|October 25, 2016
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancerSinead Toomey, Stephen F Madden, Simon J Furney, et al.
Journal of the National Cancer Institute|January 10, 2008
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trialPrudence Francis, John Crown, Angelo Di Leo, et al.
Clinical Lung Cancer|January 19, 2025
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket TrialJonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, et al.
Acta Oncologica (Stockholm, Sweden)|April 22, 2024
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter studyRosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, et al.
Breast Cancer Research : BCR|May 4, 2012
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialLynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
European Journal of Cancer (Oxford, England : 1990)|June 16, 2015
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancerAmir Sonnenblick, Prudence A Francis, Hatem A Azim, et al.
International Journal of Cancer|April 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studiesJosé A García-Saenz, Gonzalo Spera, Marina Pollán, et al.
International Journal of Radiation Oncology, Biology, Physics|March 15, 2018
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 TrialYoussef H Zeidan, Joyce G Habib, Lieveke Ameye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.
Pageof 19